Cnc.Hno

# CNC.HNO: Business Summary

CNC.HNO is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription medications and related healthcare products.

# CNC.HNO: Classification Summary

CNC.HNO is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

# CNC.HNO: Narrative

CNC.HNO maintains a strong liquidity position with $57.97 billion in cash and equivalents, representing 13.02% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 1.36 suggests the company can cover its short-term liabilities with its short-term assets.

The company's profitability is robust, with a return on equity (ROE) of 17.49% and a return on assets (ROA) of 8.36%. These figures exceed the typical performance metrics for the pharmaceutical industry, indicating strong operational efficiency and asset utilization.

CNC.HNO's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.

The company's growth trajectory is not explicitly outlined in the available data, but its strong operating cash flow of $63.32 billion and net income of $37.22 billion suggest a stable and profitable business model. The absence of recent growth initiatives or capital expenditures in the data implies a focus on maintaining current operations rather than aggressive expansion.

CNC.HNO faces low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares recently, and its diluted shares outstanding remain unchanged at 11.36 million. This suggests a stable capital structure with minimal dilution pressure.

No recent events, such as filings or transcripts, are available in the provided data to indicate significant changes in the company's operations or strategic direction. The company's financial performance appears to be consistent with its historical trends.

# CNC.HNO: Key Takeaways

- CNC.HNO has a strong liquidity position with $57.97 billion in cash and equivalents. - The company's ROE of 17.49% and ROA of 8.36% indicate strong profitability and efficient asset use. - CNC.HNO has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. - The company's revenue is concentrated in a single business segment, which may increase its exposure to market fluctuations. - CNC.HNO faces low liquidity and dilution risk, with no recent share issuance or filing-based flags. - The company's growth trajectory is not explicitly outlined, but its strong operating cash flow and net income suggest a stable business model.

# CNC.HNO: Rationales

# CNC.HNO: Inversion (DS-6)

# CNC.HNO: Self-Scoring (§A.8)

Centene Corp (CNC.O) experienced a major shift in shareholder activity, with investor ID 587 significantly altering their position as of March 31, 2026. The investor initially held 91,452 shares, valued at approximately $2.99 million, representing a 0.0017% weight in the portfolio. This position was subsequently modified to just 985 shares, valued at roughly $32,249, reducing the weight to 0.000019%. These conflicting updates, detected on June 25 and June 26, 2026, highlight a substantial reduction in the investor's stake. This change in ownership structure is notable given that Centene Corp currently has 36 top holders. The drastic reduction by investor ID 587, from a multi-million dollar position to a negligible holding, suggests a potential exit or significant rebalancing by this specific entity. While the broader shareholder base remains stable with 36 top holders, such a sharp decrease by a single investor can signal shifting sentiment or strategic reallocation within the company's investor community. In terms of risk assessment, Centene Corp has been classified with low dilution risk and low liquidity risk. These classifications, marked as new fields in the company's profile, indicate a stable financial footing regarding capital structure and cash flow management. The low severity of these risk factors suggests that the company is not facing immediate threats from share dilution or liquidity constraints, providing a baseline of financial stability despite the recent shareholder changes. Additionally, the company's taxonomy classification for both activity and economic sector has been updated to "Unclassified," a change noted with medium severity. This lack of specific classification may reflect ongoing adjustments in how the company's operations are categorized or reported. Alongside the revised AI analysis narrative, these updates contribute to a evolving profile for Centene Corp, requiring investors to monitor how these classifications might impact future analysis and reporting.

Revenue grew 19.4% year-over-year to $194.8 billion in fiscal 2026, demonstrating significant top-line expansion despite profitability challenges.

The company maintains a low leverage band with a debt-to-equity ratio of 0.87, suggesting manageable financial risk relative to equity.

Analysts assign a mean price target of $62.62, indicating modest valuation support near the current market price of $63.98.

Cash conversion ratio dropped to -0.76, significantly underperforming the cohort median of 1.2 and highlighting poor earnings quality.